|Bid||39.4000 x 600|
|Ask||39.4100 x 3300|
|Day's Range||39.3800 - 39.5200|
|52 Week Range||31.2400 - 40.4400|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.12%|
On August 28, 2017, Gilead Sciences entered a definitive agreement to acquire Kite Pharma (KITE) for $180 per share in cash.
Merck's Pharmaceuticals segment contributed ~88.2% of total revenues in 2Q17, reporting $8.76 billion.
Eli Lilly & Co. (LLY) reported revenues of ~$5.8 billion during 2Q17, reflecting 8.0% growth compared to its revenues in 2Q16.